Drugs / Bifidobacterium quadruple live tablets
Bifidobacterium quadruple live tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07686861 | Jul 2026 → Jul 2027 expected | cirrhosis of liver | Peking University First Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium quadruple live tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07686861 ↗ |
| Modality | Other / unclassified | “adding Bifidobacterium quadruple probiotics can improve infection control rates and reduce SBP recurrence” NCT07686861 ↗ |
| Route | Oral | “Bifidobacterium quadruple live tablets orally” NCT07686861 ↗ |